Trial · NCT03148236

Vitamin C in Atrial Fibrillation Ablation

NCT03148236, Phase 2, Completed, Virginia Commonwealth University; results first posted 2019-04-16

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Vitamin C in Atrial Fibrillation Ablation. Trials, record NCT03148236. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03148236

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Vitamin C in Atrial Fibrillation Ablation
NCT number: NCT03148236
Status: Completed
Phases: Phase 2
Enrollment: 20 participants, actual
Lead sponsor: Virginia Commonwealth University
Conditions: Atrial Fibrillation Ablation
Interventions: Vitamin C, Placebo
First posted: 2017-05-10
Last updated: 2019-04-16
Results first posted: 2019-04-16

Source ClinicalTrials.gov

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Creatinine Levels	Baseline to 24 hours	Change in Kidney Function
Primary	Change in Plasma Levels of Ascorbic Acid	baseline to 24 hours	Change in plasma levels of ascorbic acid
Primary	Change in hsCRP	baseline to 24 hours	Biomarker of inflammation
Primary	Change in Interleukin (IL-6)	baseline to 24 hours	Biomarker of inflammation
Primary	Change in Von Willebrand Factor (vWF)	baseline to 24 hours	Biomarker of blood vessel damage
Primary	Change in Creatinine Levels	Baseline to 30 days	Change in kidney function
Primary	Change in Plasma Ascorbic Acid Level	Baseline to 30 days	Change in plasma ascorbic acid level
Primary	Change in hsCRP	baseline to 30 days	Biomarker of inflammation
Primary	Change in Interleukin (IL-6)	baseline to 30 days	Biomarker of inflammation
Primary	Change in Von Willebrand Factor (vWF)	baseline to 30 days	Biomarker of blood vessel damage

1 to 10 of 11Source ClinicalTrials.gov

See all 11 registered outcomes

Outcomes11

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change in Creatinine Levels	Baseline to 24 hours	mg/dL	MEDIAN
PRIMARY	Change in Plasma Levels of Ascorbic Acid	baseline to 24 hours	micromolar	MEDIAN
PRIMARY	Change in hsCRP	baseline to 24 hours	mg/L	MEDIAN
PRIMARY	Change in Interleukin (IL-6)	baseline to 24 hours	pg/mL	MEDIAN
PRIMARY	Change in Von Willebrand Factor (vWF)	baseline to 24 hours	micrograms/mL	MEDIAN
PRIMARY	Change in Creatinine Levels	Baseline to 30 days	mg/dL	MEDIAN
PRIMARY	Change in Plasma Ascorbic Acid Level	Baseline to 30 days	micromolar	MEDIAN
PRIMARY	Change in hsCRP	baseline to 30 days	mg/L	MEDIAN
PRIMARY	Change in Interleukin (IL-6)	baseline to 30 days	pg/mL	MEDIAN
PRIMARY	Change in Von Willebrand Factor (vWF)	baseline to 30 days	micrograms/mL	MEDIAN

1 to 10 of 11Source ClinicalTrials.gov

See all 11 outcomes

Results by group22

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Creatinine Levels	Vitamin C	-0.1	Inter-Quartile Range -0.2 to -0.1	mg/dL
Change in Creatinine Levels	Placebo	-0.1	Inter-Quartile Range -0.2 to 0	mg/dL
Change in Plasma Levels of Ascorbic Acid	Vitamin C	267	Inter-Quartile Range 98 to 597	micromolar
Change in Plasma Levels of Ascorbic Acid	Placebo	-4	Inter-Quartile Range -8 to -1	micromolar
Change in hsCRP	Vitamin C	5.31	Inter-Quartile Range 4.48 to 7.92	mg/L
Change in hsCRP	Placebo	16.01	Inter-Quartile Range 9.40 to 29.29	mg/L
Change in Interleukin (IL-6)	Vitamin C	13.3	Inter-Quartile Range 6.6 to 29.4	pg/mL
Change in Interleukin (IL-6)	Placebo	6.6	Inter-Quartile Range 2.6 to 12.1	pg/mL
Change in Von Willebrand Factor (vWF)	Vitamin C	0.4	Inter-Quartile Range -1.3 to 4.8	micrograms/mL
Change in Von Willebrand Factor (vWF)	Placebo	0.4	Inter-Quartile Range -2.5 to 2.5	micrograms/mL

1 to 10 of 22Source ClinicalTrials.gov

See all 22 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Vitamin C	10
Overall Study	STARTED	Placebo	10
Overall Study	COMPLETED	Vitamin C	10
Overall Study	COMPLETED	Placebo	10
Overall Study	NOT COMPLETED	Vitamin C	0
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Pericarditis	Cardiac disorders	Vitamin C	1	10	1
other	Pericarditis	Cardiac disorders	Placebo	1	10	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Vitamin C	0	10
Total, all-cause mortality	Placebo	0	10
Total, other adverse events	Vitamin C	1	10
Total, other adverse events	Placebo	1	10
Total, serious adverse events	Vitamin C	0	10
Total, serious adverse events	Placebo	0	10

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
32013700	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Vitamin C vs Placebo: deaths from any cause	Trial comparisons
Vitamin C vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03148236

GET https://conductscience.org/api/trials/v1/NCT03148236/results?page=2

API reference For AI assistants